Antidiabetic Thiazolidinediones Market 2028 By Type, End User, and Geography | The Insight Partners

report image

Antidiabetic Thiazolidinediones Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Rosiglitazone, Pioglitazone); End User (Hospital, Clinic, Others ), and Geography

Report Code: TIPRE00021679 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming


Thiazolidinediones, also known as glitazones, are a type of medication that can be used to treat type 2 diabetes. They're a kind of hypoglycemic medication that's taken orally.


The antidiabetic thiazolidinediones market is driving due to the rising prevalence of diabetes and rising geriatric population. However, presence of other diabetes medicines is expected to hamper the growth of the global antidiabetic thiazolidinediones market.


The "Antidiabetic Thiazolidinediones Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of antidiabetic thiazolidinediones market with detailed market segmentation by end user and type. The antidiabetic thiazolidinediones market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in antidiabetic thiazolidinediones market and offers key trends and opportunities in the market.


The antidiabetic thiazolidinediones market is segmented on the basis of type and end user. Based on type, the market is segmented as rosiglitazone and pioglitazone. On the basis of end user, the market is categorized as hospital, clinic, and others.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Antidiabetic thiazolidinediones market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Antidiabetic thiazolidinediones market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Antidiabetic thiazolidinediones market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Antidiabetic thiazolidinediones market in these regions.

Get more information on this report :


The report covers key developments in the Antidiabetic thiazolidinediones market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Antidiabetic thiazolidinediones market are anticipated to have lucrative growth opportunities in the future with the rising demand for Antidiabetic thiazolidinediones in the global market. Below mentioned is the list of few companies engaged in the Antidiabetic thiazolidinediones market.

The report also includes the profiles of key players in Antidiabetic thiazolidinediones market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Bristol-Myers Squibb
  •   Pfizer
  •   Boehringer Ingelheim
  •   Eli Lilly
  •   Merck and Co.
  •   AstraZeneca
  •   GlaxoSmithKline
  •   Sanofi
  •   Takeda Pharmaceuticals
  •   Novo Nordisk

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Get more information on this report :

The List of Companies

1. Bristol-Myers Squibb
2. Pfizer
3. Boehringer Ingelheim
4. Eli Lilly
5. Merck and Co.
6. AstraZeneca
7. GlaxoSmithKline
8. Sanofi
9. Takeda Pharmaceuticals
10. Novo Nordisk
11. Mylan Pharmaceuticals Inc.
12. Teva Pharmaceuticals USA, Inc.
13. Aurobindo Pharma Limited
14. Solco Healthcare U.S., LLC
15. Macleods Pharmaceuticals Limited
16. PuraCap Pharmaceutical LLC
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000 $2700
  • $4550 $4095
  • $6550 $5568
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount